Huang Qin Tang Chinese Brew may lessen Chemotherapy Side-effects
A primeval Chinese brew might aid in reducing gut damage arising due to chemotherapy administered to colorectal cancer patients, according to study scientists from the Yale Univ. School of Medicine, U.S.
For meeting the burgeoning customer demands, scientists in the area of traditional medicine are working to corroborate the efficiency of primordial medications employing Western styled animal tests as well as human scientific studies.
According to a paper printed in ‘Science Translational Medicine’ the investigators stated that the cancer-afflicted rodents were given the Chinese concoct following chemotherapy session employing irinotecan which has established toxic effects on the intestines and causal to loose bowels.
Study researchers pointed out that when cancer-ridden rodents were administered chemotherapy it caused tumor shrinkage however additionally was contributory to substantial damage to the gut lining in animals.
Following just days post-treatment that involved usage of PHY906 medication, there was noteworthy restoration of damage caused to the gut lining among the rodents.
PHY906 is a lab formula which is a 1800 years old Chinese formulation that contains a purplish bloom known as skullcap, peonies, buckthorn tree produce and licorice. Known as Huang Qin Tang, the formulation has since long been deployed for treating puking, queasiness and loose bowels.
Elucidating their study, lead author, Yung-Chi Cheng spoke about how Irinotecan single-handedly diminished tumor development however when it is coalesced with PHY906 it could additionally lower tumor development.
On its own, PHY906 does not lessen tumor development and has to be employed in merger with chemotherapy.
Colorectal cancer garners the third position as the most lethal form of cancer following lung and stomach cancers and causal to 6399000 fatalities worldwide during 2004, as per information provided by the WHO.
As per data furnished by the ACS (American Cancer Society), the monetary burden arising due to colorectal cancer in regards to untimely fatality and disablement is ninety-nine billion dollars yearly, barring direct therapy expenses.
Cheng further added that their research group has since concluded a small-scaled scientific study employing the brew on seventeen colorectal cancer patients. The outcomes of the phase I, II scientific study has shown promise and the investigators would now proceed to large-scaled scientific trial.
Cheng is a stake-owner in the firm PhytoCeutica that is involved in the development of conventional Chinese medicine into cancer therapy drugs and is a PHY906 license-holder.
